All In Biotech

Drugs by condition

Drugs approved for sickle cell disease

Brand-name prescription drugs and biologics whose FDA label lists sickle cell disease as an approved use. Matched on the label phrases: "sickle cell".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

8

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

3

New molecular entities and new biologics

In development

10

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for sickle cell disease.

  • Xromi (Hydroxyurea) · Nova Labs LTD Priority reviewOrphanApr 4, 2024
  • Ferriprox (Deferiprone) · Chiesi Accelerated approvalOrphanMay 19, 2020
  • Adakveo (Crizanlizumab-Tmca) · Novartis Pharms Corp NovelBreakthrough therapyPriority reviewOrphanNov 15, 2019
  • Siklos (Hydroxyurea) · Theravia OrphanDec 21, 2017
  • Endari (L-Glutamine) · Emmaus Medcl OrphanJul 7, 2017

All approved drugs for sickle cell disease, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 4 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Iron Chelator (3)

Antimetabolite (3)

  • Droxia Hydroxyurea · Waylis Therap · 1967
  • Xromi Hydroxyurea · Nova Labs LTD · 2024
  • Siklos Hydroxyurea · Theravia · 2017

Selectin Blocker (1)

  • Adakveo Crizanlizumab-Tmca · Novartis Pharms Corp · 2019

Amino Acid (1)

  • Endari L-Glutamine · Emmaus Medcl · 2017

Drugs in development for sickle cell disease

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • FT-4202EtavopivatPhase 36 trials

    Forma Therapeutics, Inc. · Sickle Cell Disease, Thalassemia

  • Exa-celPhase 31 trial

    Vertex Pharmaceuticals · Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies

  • IMR-687Tovinontrine, CRD-750Phase 23 trials

    Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases

  • HBI-002Phase 22 trials

    Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell

  • TebapivatAG-946Phase 22 trials

    Agios Pharmaceuticals, Inc. · Myelodysplastic Syndromes, Sickle Cell Disease

  • AnumigilimabPhase 21 trial

    CSL Behring · Sickle Cell Disease

  • BEAM-101Phase 21 trial

    Beam Therapeutics Inc. · Sickle Cell Disease

  • BMS-986470Phase 21 trial

    Bristol Myers Squibb · Anemia, Sickle Cell, Healthy Volunteers

  • CSL889Phase 21 trial

    CSL Behring · Sickle Cell Disease Vaso-occlusive Crisis

  • ITU512Phase 21 trial

    Novartis · Sickle Cell Disease

2 discontinued brand-name drugs whose label still names it

More on sickle cell disease: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Hemophilia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.